Trials have already shown that Novo Nordisk’s semaglutide can cut the risk of cardiovascular events and kidney disease. Now a study from the University of Oxford indicates that the company’s semaglutide type 2 diabetes drug Ozempic can reduce the risk of dementia compared with another popular diabetes medicine.
Sildenafil, known as Viagra, may help prevent memory-related problems by improving cerebral blood flow and blood vessel function, reducing the risk of vascular dementia. A University of Oxford study, highlighted by Dr. Praveen Gupta and Dr. Manjari Tripathi, shows promise but requires further researc
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
The first participant enrolled on Friday in the PLATINUM (Placebo-controlled randomized trial of tecovirimat in nonhospitalised monkeypox patients) trial, building off animal model successes that led to FDA and UK approvals, and follows the NIH’s National Institute of Allergy and Infectious Diseases announcement that it’s launching a similar trial in the US next week.
MiroBio was spun out of the University of Oxford in 2019 to develop a new class of medicines, called immune checkpoint agonists, to treat autoimmune diseases by restoring balance to the immune system. The company was co-founded by OSE and Tim Funnell, OSE’s entrepreneur in residence at the time, and Samsara BioCapital, working closely with MiroBio’s scientific founders – Simon Davis, professor of Molecular Immunology, MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield professor of Clinical Medicine.
PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct a feasibility trial to investigate whether anti-tumor necrosis factor (TNF) therapy, administered at the time of surgery, can reduce or prevent post operative delirium/cognitive deficit (“post-operative delirium”).
The novel coronavirus vaccine has been developed at Caltech and The University of Oxford. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities.
The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has...
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Novavax is participating in a stage of the COVID-19 Vaccine Schedule Combinations (Com-COV) program initiated by the University of Oxford and supported by the UK Vaccine Taskforce and the National Institute for Health and Care Research. Novavax' protein-based COVID-19 vaccine, NVX-CoV2373, is one of two COVID-19 vaccines that will be studied as a third dose booster in adolescents aged 12 through 15 years to evaluate the potential use of vaccines from different manufacturers to achieve immune protection against COVID-19.